<DOC>
	<DOCNO>NCT01989429</DOCNO>
	<brief_summary>M5181 - novel vitamin D3 analogue - currently development treatment plaque psoriasis develop topical ointment formulation ( M518101 ) Clinical non-clinical study indicate M5181 effective treatment plaque psoriasis . Based result previous phase II trial phase III trial design evaluate efficacy safety 8-week treatment period 50 Î¼g/g M518101 large population patient stable plaque psoriasis .</brief_summary>
	<brief_title>Efficacy Study Comparing Topical M518101 Vitamin D3 Adult Psoriasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Male female patient age 18 year old day signing inform consent form ( ICF ) Psoriasis patient 20 % affect body surface area ( BSA ) ( include face scalp ) Investigator Global Assessment ( IGA ) moderate severe suitable topical therapy Pregnant lactating female ; Patients know allergic reaction , irritation sensitivity vitamin D3 derivative drug hypersensitivity component investigational product ; Patients treat topical steroid , topical immunosuppressive/ immunomodulative drug , topical vitamin D3 derivative , topical retinoids , anthralin , coal tar ( except use shampoo ) salicylic acid within 14 day randomization Patients , opinion investigator , clinically relevant history presence disease , skin disorder , chronic medical condition well controlled surgical history may interfere conduct trial Patients whose calcium test screen exceed upper limit reference range ( include serum calcium , albumin , phosphate , parathyroid hormone ) ; Patients use study drug ( include experimental biologics ) and/or participated clinical trial within last 60 day day randomization Patients treat biologics psoriasis within 30 day 5 halflives ( whichever longer ) biologic day randomization long document halflife biologic use calculate 5 halflives ; Patients treat phototherapy ( laser , oral steroid , oral retinoid , oral immunosuppressive/immunomodulative drug , cytostatics , cyclosporine methotrexate within 30 day randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>Vitamin D3</keyword>
	<keyword>topical</keyword>
	<keyword>ointment</keyword>
</DOC>